As clinical research begins to pivot back from a single-minded focus on COVID-19 therapeutics and vaccines, the life sciences field is adapting to the new research landscape. In a recent Life Science Leader article, Denise Juliano lays out five important trends to watch in therapeutic development and market access. The first trend is a push toward using real-world data (RWD) and real-world evidence (RWE) in clinical trials to shorten timelines.
According to Juliano, “But it’s rare for life sciences companies to have access to the breadth of data that are needed for discovery, research, and proof of value. That’s why, according to a 2020 Deloitte benchmarking survey of the pharmaceutical industry, more than 80% of respondents said they intended to enter into partnerships with data and data science companies. We expect this trend to get turbocharged as research into new cures is reinvigorated.”
Read more by clicking here.
(Source: Life Science Leader, May 2nd, 2022)
